Etanercept biosimilar - Pfizer

Drug Profile

Etanercept biosimilar - Pfizer

Alternative Names: Lifmior

Latest Information Update: 30 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis

Most Recent Events

  • 15 Dec 2016 Committee for Medicinal Products for Human Use (CHMP) of EMA recommends approval of Etanercept biosimilar for Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Plaque psoriasis (In children, In adolescents and In adults), Ankylosing spondylitis and Spondylarthritis in European Union
  • 14 Dec 2016 Preregistration for Rheumatoid arthritis, Plaque psoriasis (In children, In adolescents, adults), Spondylarthritis, Ankylosing spondylitis, Psoraitic arthritis and Juvenile rheumatoid arthritis in European Union (SC) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top